Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Transl Res. 2011 Feb;3(2):166-79. Epub 2010 Dec 26.

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.

Abstract

Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. However, the molecular mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood. In this review, we summarize our understanding of the molecular and biological events that underpin the anticancer effects of HDAC inhibitors and the outcomes of recent clinical trials involving these drugs.

KEYWORDS:

HDAC inhibitor; MS-275; acetylation; cancer; depsipeptide (FK228); vorinostat (SAHA)

PMID:
21416059
[PubMed]
PMCID:
PMC3056563
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk